Arrowhead Pharmaceuticals Reports Q4 2026 Results with REDEMPLO Commercial Launch and Debt Refinancing
Arrowhead Pharmaceuticals (ARWR) reported a net loss of $724.2 million for the fourth quarter of 2026, primarily driven by a one-time $215 million expense related to a priority review voucher acquisition. Total revenue fell to $450.8 million from $829.4 million in the prior year, a decline attributed to the absence of significant collaboration payments received during the previous fiscal period. Despite the net loss, the company showed strong commercial momentum for its REDEMPLO product, which saw new-to-brand prescriptions increase by 63% over the prior quarter. The company also successfully refinanced $400 million in debt through Sixth Street, significantly reducing interest costs from a previous 15% rate to SOFR plus 5.5%. With $1.2 billion in cash and investments, Arrowhead is positioned to support its transition toward potential blockbuster market launches.
Tickers: $ARWR
Topics: earnings report net loss pharmaceuticals product sales revenue decrease